特发性肉芽肿性乳腺炎:基于土耳其临床分类的治疗和随访方法的共识报告。

IF 2.1 4区 医学 Q2 OBSTETRICS & GYNECOLOGY
Breast Care Pub Date : 2025-08-01 Epub Date: 2025-03-03 DOI:10.1159/000544967
Mustafa Emiroglu, Kenan Cetin, Kerim Bora Yilmaz, Mehmet Velidedeoglu, Sadullah Girgin, Alper Akcan, Ozgur Aytac, Murat Akın, Hande Koksal, Neslihan Cabioglu, Nuh Zafer Canturk, Bahadır Gulluoglu
{"title":"特发性肉芽肿性乳腺炎:基于土耳其临床分类的治疗和随访方法的共识报告。","authors":"Mustafa Emiroglu, Kenan Cetin, Kerim Bora Yilmaz, Mehmet Velidedeoglu, Sadullah Girgin, Alper Akcan, Ozgur Aytac, Murat Akın, Hande Koksal, Neslihan Cabioglu, Nuh Zafer Canturk, Bahadır Gulluoglu","doi":"10.1159/000544967","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The second consensus study on idiopathic granulomatous mastitis (IGM) aimed to establish treatment options based on the clinical classification proposed in the first consensus, standardize criteria for treatment discontinuation, and develop follow-up protocols.</p><p><strong>Method: </strong>A structured methodology, identical to the first consensus study, was employed. An 11-member working group of breast surgeons experienced in IGM from various clinics across the country was formed. The modified Delphi method was used, with a consensus threshold of 80% agreement.</p><p><strong>Results: </strong>Three voting rounds were conducted to develop the IGM treatment algorithm. In Round 1, observation was established as the first-line option for Type 1 disease (81%) and pregnancy/lactation cases (85%). Round 2 achieved consensus on systemic steroids (SS) as the first-line treatment for Type 3 cases (84%), combination therapies for resistant cases (82%), and reclassification of recurrent cases to guide treatment planning (94%). In Round 3, consensus was reached on the use of immunosuppressive therapy (IMT) for cases where steroids are contraindicated in Type 3 (81%), the use of IMT for resistant cases (93%), avoiding surgery as the first-line option for Type 1 cases (81%), and requiring complete clinical and radiological response before discontinuing treatment (81%). However, no consensus was reached on the first-line treatment for Type 2 disease.</p><p><strong>Conclusion: </strong>This consensus study successfully developed a treatment algorithm for IGM, prioritizing observation for Type 1 disease and cases involving pregnancy or lactation, and recommending systemic steroids (SS) and immunosuppressive therapies for Type 3 cases. The findings underscore the critical importance of achieving complete clinical and radiological remission before discontinuing treatment. However, the lack of consensus on the treatment of Type 2 disease highlights the need for further research into this challenging subtype.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 4","pages":"248-255"},"PeriodicalIF":2.1000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377798/pdf/","citationCount":"0","resultStr":"{\"title\":\"Idiopathic Granulomatous Mastitis: A Consensus Report on Treatment and Follow-Up Approaches Based on the Turkish Clinical Classification.\",\"authors\":\"Mustafa Emiroglu, Kenan Cetin, Kerim Bora Yilmaz, Mehmet Velidedeoglu, Sadullah Girgin, Alper Akcan, Ozgur Aytac, Murat Akın, Hande Koksal, Neslihan Cabioglu, Nuh Zafer Canturk, Bahadır Gulluoglu\",\"doi\":\"10.1159/000544967\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>The second consensus study on idiopathic granulomatous mastitis (IGM) aimed to establish treatment options based on the clinical classification proposed in the first consensus, standardize criteria for treatment discontinuation, and develop follow-up protocols.</p><p><strong>Method: </strong>A structured methodology, identical to the first consensus study, was employed. An 11-member working group of breast surgeons experienced in IGM from various clinics across the country was formed. The modified Delphi method was used, with a consensus threshold of 80% agreement.</p><p><strong>Results: </strong>Three voting rounds were conducted to develop the IGM treatment algorithm. In Round 1, observation was established as the first-line option for Type 1 disease (81%) and pregnancy/lactation cases (85%). Round 2 achieved consensus on systemic steroids (SS) as the first-line treatment for Type 3 cases (84%), combination therapies for resistant cases (82%), and reclassification of recurrent cases to guide treatment planning (94%). In Round 3, consensus was reached on the use of immunosuppressive therapy (IMT) for cases where steroids are contraindicated in Type 3 (81%), the use of IMT for resistant cases (93%), avoiding surgery as the first-line option for Type 1 cases (81%), and requiring complete clinical and radiological response before discontinuing treatment (81%). However, no consensus was reached on the first-line treatment for Type 2 disease.</p><p><strong>Conclusion: </strong>This consensus study successfully developed a treatment algorithm for IGM, prioritizing observation for Type 1 disease and cases involving pregnancy or lactation, and recommending systemic steroids (SS) and immunosuppressive therapies for Type 3 cases. The findings underscore the critical importance of achieving complete clinical and radiological remission before discontinuing treatment. However, the lack of consensus on the treatment of Type 2 disease highlights the need for further research into this challenging subtype.</p>\",\"PeriodicalId\":9310,\"journal\":{\"name\":\"Breast Care\",\"volume\":\"20 4\",\"pages\":\"248-255\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377798/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Care\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000544967\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/3/3 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000544967","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:特发性肉芽肿性乳腺炎(IGM)第二次共识研究旨在根据第一次共识提出的临床分类建立治疗方案,规范停药标准,制定随访方案。方法:采用与第一项共识研究相同的结构化方法。一个由11名在IGM方面经验丰富的乳房外科医生组成的工作小组成立了,他们来自全国各地的不同诊所。采用改进的德尔菲法,共识阈值为80%。结果:进行了三轮投票来制定IGM处理算法。在第1轮中,观察被确定为1型疾病(81%)和妊娠/哺乳期病例(85%)的一线选择。第2轮的共识是,全体性类固醇(SS)作为3型病例的一线治疗(84%),耐药病例的联合治疗(82%),复发病例的重新分类以指导治疗计划(94%)。在第3轮中,对3型类固醇禁忌症患者使用免疫抑制治疗(IMT)达成了共识(81%),对耐药病例使用IMT(93%),避免手术作为1型病例的一线选择(81%),并且在停止治疗之前需要完全的临床和放射学反应(81%)。然而,对于2型疾病的一线治疗尚未达成共识。结论:本共识研究成功制定了IGM的治疗算法,优先观察1型疾病和妊娠或哺乳期病例,建议对3型病例进行全身类固醇(SS)和免疫抑制治疗。研究结果强调了在停止治疗前达到临床和放射学完全缓解的重要性。然而,对2型疾病的治疗缺乏共识,这凸显了对这一具有挑战性的亚型进行进一步研究的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Idiopathic Granulomatous Mastitis: A Consensus Report on Treatment and Follow-Up Approaches Based on the Turkish Clinical Classification.

Objective: The second consensus study on idiopathic granulomatous mastitis (IGM) aimed to establish treatment options based on the clinical classification proposed in the first consensus, standardize criteria for treatment discontinuation, and develop follow-up protocols.

Method: A structured methodology, identical to the first consensus study, was employed. An 11-member working group of breast surgeons experienced in IGM from various clinics across the country was formed. The modified Delphi method was used, with a consensus threshold of 80% agreement.

Results: Three voting rounds were conducted to develop the IGM treatment algorithm. In Round 1, observation was established as the first-line option for Type 1 disease (81%) and pregnancy/lactation cases (85%). Round 2 achieved consensus on systemic steroids (SS) as the first-line treatment for Type 3 cases (84%), combination therapies for resistant cases (82%), and reclassification of recurrent cases to guide treatment planning (94%). In Round 3, consensus was reached on the use of immunosuppressive therapy (IMT) for cases where steroids are contraindicated in Type 3 (81%), the use of IMT for resistant cases (93%), avoiding surgery as the first-line option for Type 1 cases (81%), and requiring complete clinical and radiological response before discontinuing treatment (81%). However, no consensus was reached on the first-line treatment for Type 2 disease.

Conclusion: This consensus study successfully developed a treatment algorithm for IGM, prioritizing observation for Type 1 disease and cases involving pregnancy or lactation, and recommending systemic steroids (SS) and immunosuppressive therapies for Type 3 cases. The findings underscore the critical importance of achieving complete clinical and radiological remission before discontinuing treatment. However, the lack of consensus on the treatment of Type 2 disease highlights the need for further research into this challenging subtype.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Breast Care
Breast Care 医学-妇产科学
CiteScore
4.40
自引率
4.80%
发文量
45
审稿时长
6-12 weeks
期刊介绍: ''Breast Care'' is a peer-reviewed scientific journal that covers all aspects of breast biology. Due to its interdisciplinary perspective, it encompasses articles on basic research, prevention, diagnosis, and treatment of malignant diseases of the breast. In addition to presenting current developments in clinical research, the scope of clinical practice is broadened by including articles on relevant legal, financial and economic issues.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信